Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue, Oluwatayo Adeoye, Ayodeji Johnson, Arushi Khurana, Jithma Abeykoon, Urshila Durani, Mazie Tsang, Allison Rosenthal, Talal Hilal, Javier Munoz, Patrick Johnston, Han Tun, Grzegorz Nowakowski, James Cerhan, Richard Godby, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2025-4494

Published: 2025

Journal Articles

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2025-2741

Published: 2025

Journal Articles

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Blood (2025) 146 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2025-1798

Published: 2025

Journal Articles

Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

Blood (2025) 146 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2025-1007

Published: 2025

Journal Articles

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Ayo Falade, Abiola Bolarinwa, Oluwatayo Adeoye, Muhammad Yousuf, Allison Rosenthal, Mazie Tsang, Madiha Iqbal, Daniel Lachance, Rebecca King, Yucai Wang, Micallef Ivana, Robert Spinner, Thomas Habermann, Grzegorz Nowakowski, Arushi Khurana, Patrick Johnston

Blood (2025) 146 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2025-6306

Published: 2025

Journal Articles

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Blood (2025) 146 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2025-3905

Published: 2025

Journal Articles

Low-dose lenalidomide for maintenance of remission in primary central nervous system lymphoma: A single-center experience.

Michael Randall, Mazie Tsang, Chitoh Yung, James Rubenstein

Blood (2025) 146 (Supplement 1): 900.

https://doi.org/10.1182/blood-2025-900

Published: 2025

Journal Articles

Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study

Kanishka Uttam Chandani, Usman Ilyas, Ritu C. Tated, Pragyat Futela, Dhruvi Joshi, Apoorva Kondapally, Jatin Thukral, Sooraj Srirangadhamu Gopu, Donald Northfelt, Surbhi Shah, Theresa Kinard, Lawrence Williams, Mazie Tsang, Talal Hilal

Blood (2025) 146 (Supplement 1): 4892.

https://doi.org/10.1182/blood-2025-4892

Published: 2025

Journal Articles

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Blood (2025) 146 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2025-5667

Published: 2025

Journal Articles

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Blood (2025) 146 (Supplement 1): 786.

https://doi.org/10.1182/blood-2025-786

Published: 2025

Journal Articles

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Ajay Major, Esprit Ma, Anthony Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Pophali, Sally Werner, Rebecca Bungay, Dominick Latremouille-Viau, Annie Guerin, Carolina Reyes, Mei Wu, Lourenia Cassoli, Pallawi Torka

Blood (2025) 146 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2025-6181

Published: 2025

Journal Articles

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Blood (2025) 146 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2025-5354

Published: 2025

Journal Articles

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

Blood (2024) 144 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2024-198200

Published: 2024

Journal Articles

Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors

Rodrigo Fonseca, Diana Zamora, Fan Leng, Christie C Ngo, Jose F. Leis, Mazie Tsang, Talal Hilal

Blood (2024) 144 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2024-201245

Published: 2024

Journal Articles

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2024-201078

Published: 2024

Journal Articles

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2024) 144 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2024-210594

Published: 2024

Journal Articles

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Mazie Tsang, Urshila Durani, Jonathan R Day, Melissa C. Larson, Matthew Holets, Kathleen J Yost, Jonathon B. Cohen, Jonathan W. Friedberg, Izidore S. Lossos, Peter Martin, Brad S. Kahl, Thomas M. Habermann, Loretta Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Carla Casulo, Matthew J. Maurer

Blood (2024) 144 (Supplement 1): 7598.

https://doi.org/10.1182/blood-2024-210968

Published: 2024

Journal Articles

Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment

Blood (2023) 142 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2023-181866

Published: 2023

Journal Articles

Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2023) 142 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2023-183007

Published: 2023

Journal Articles

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Côme Bommier, Mazie Tsang, Brie N. Noble, Carrie Thompson, Christopher Strouse, Carla Casulo, Eric Mou, Melissa C. Larson, Brianna Gysbers, Allison C. Rosenthal, Andrew L. Feldman, Matthew J. Maurer, Kathleen Yost, Susan L. Slager, Brian K. Link, Thomas M. Habermann, Amylou Constance Dueck, James R. Cerhan

Blood (2023) 142 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2023-186862

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Low-dose lenalidomide for maintenance of remission in primary central nervous system lymphoma: A single-center experience.

Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment

Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only